Visit coronavirus.gov for the latest Coronavirus Disease (COVID-19) updates.
Read the 30 Days to Slow the Spread Guidance - PDF (versión en Español - PDF).

You are here

Evidence-Based Resource Summary

Strength of Evidence: 
4 out of 4
4 out of 4
Year Published: 
2012

Hormone Therapy With Combined Estrogen and Progestin: Preventive Medication in Postmenopausal Women

Description of Resource: 
The U.S. Preventive Services Task Force (USPSTF) recommends against the use of combined estrogen and progestin for the prevention of chronic conditions in postmenopausal women. This recommendation applies only to postmenopausal women who are considering hormone therapy for the primary prevention of chronic medical conditions. This recommendation is not about the use of hormone therapy to treat menopausal symptoms, such as hot flashes or vaginal dryness, and it does not apply to women younger than age 50 who have had surgical menopause. This is a D recommendation, which means the USPSTF recommends against the service. There is moderate or high certainty that the service has no net benefit or that the harms outweigh the benefits.

Evidence-Based Resource Details

help Learn more about EBR criteria
Developed By: 
U.S. Preventive Services Task Force
Developer Type: 
Federal Government
Healthy People 2020 Topic Area(s): 
Maternal, Infant, and Child Health
Resource Type: 
Systematic Review
Citation: 
U.S. Preventive Services Task Force. Menopausal Hormone Therapy: Preventive Medication recommendation statement [Internet]. 2012 Oct [cited 2014 Jan 8]. Available from: http://www.uspreventiveservicestaskforce.org/uspstf12/menohrt/menohrtfinalrstab1-2.htm